Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Caisse des Depots and Sanofi Sign an Agreement

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Agreement with Sanofi to help with Biocitech’s development.

The Caisse des Depots have signed an agreement with Sanofi to cover the Caisse des Depots buy-back of Biocitech, the technology park dedicated to life sciences.

Biocitech is a key element in the development of the biotechnology sector in the Seine-Saint-Denis department and in the Ile de France region. Sanofi was represented by general secretary Philippe Peyre.

Jean-Pierre Jouyet, general manager and Stephane Keita, territorial and network development manager represented the Caisse des Depots.

Claude Bartolone, president of the French National Assembly and representative for the Seine-Saint-Denis department attended today’s official signing. He was joined by Corinne Valls, vice-president of the Seine-Saint-Denis departmental council and Mayor of Romainville and Stephane Troussel, president of the Seine-Saint-Denis departmental council.

Gerard Cosme, president of the Est Ensemble metropolitan area also attended the ceremony with the Biocitech SAS president, Jean-Francois Boussard.

In 2002, Sanofi decided to launch an industrialization operation in partnership with the local authorities. Biocitech was fully established in 2003 and demonstrates Sanofi’s commitment to rehabilitate the area. The biotechnology and life sciences park currently hosts 25 companies, which employ around 350 people in Romainville.

The technology park is also a key element in the Medicen Paris Region network, the Greater Paris region’s world-class competitiveness hub for health and new therapies. Biocitech provides a range of specific services for firms operating within biotechnology, biopharmaceuticals, fine chemicals, medical and in vitro diagnostics and medical devices.

Today’s agreement has been established in collaboration with local authorities and the Ile de France institutions. Their aim is to develop the technology park. A new company, Biocitech Immobilier, will own it. The Caisse des Depots will retain an initial 40 per cent share.

They will acquire the remaining 60 per cent of the shares after further redevelopment is complete in the Galien building. Galapagos, one of the resident companies, will move into the Galien building in 2015.

Additionally, a portion of the site, representing 3.4 hectares (9.21 acres) will be rehabilitated and reorganized, in order to promote the economic development of the area. The objective is to turn Biocitech into an open campus. The firms installed at Biocitech will complement one another and generate strong synergies and collaborations.

Some key features at Biocitech:

• A unique blend of real estate and industrial expertise
• A service for young and thriving innovative companies
• A tailored offer for biotechnology SMEs, for activities such as imaging, medical devices, diagnostics and environment
• An active and long-lasting ecosystem, based on the residents’ commitment

This agreement is the start of a new growth dynamic. It is supported by an investment plan to optimize and rationalize the buildings.

All the partners will get together in order to have the residents stay as long as possible and to attract new tenants, while adding value to the real estate reserve.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

2012 in Review: Biocitech Focuses on Collaboration with Regional Players
In 2012, the technology park in Paris, France signed cooperation agreements with the Paris public hospital system, France's development research institute and the Paris Chamber of Commerce to provide tenant businesses with tools for development.
Tuesday, May 14, 2013
PupPharma Moves into the Biocitech Science Park
PupPharma is a CRO specialized in perinatal and pediatric pharmacology.
Friday, June 24, 2011
Biocitech Announces the Arrival of OCT Santé on its Campus
Biocitech, the Parisian life sciences technology park, announce the installation of a new firm, OCT Santé, on its campus. OCT Santé is the 25th company to relocate to Biocitech, where the occupation rate is now over 90 per cent.
Tuesday, December 07, 2010
Biocitech Life Science Park Welcomes Chem-X-Infinity and Spectralys Innovation
Two new arrivals add to Biocitech's success in attracting companies to the Paris life science park.
Tuesday, November 25, 2008
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!